Literature DB >> 9714564

Characterization of three episodic ataxia mutations in the human Kv1.1 potassium channel.

P Zerr1, J P Adelman, J Maylie.   

Abstract

Episodic ataxia (EA) is a rare inherited neurological disorder due to mutation in the voltage-dependent Kv1.1 potassium channel. In nine unrelated families, a different missense point mutation at highly conserved positions has been reported. We have previously characterized six of the EA mutants. In this study, three recently identified mutations were introduced into the human Kv1.1 cDNA and expressed in Xenopus oocytes. Compared to wild type, T226A and T226M reduced the current amplitude by > 95%, shifted the voltage dependence by 15 mV, and slowed activation and deactivation kinetics. Currents from G311S were approximately 25% of wild type, less steeply voltage-dependent and had more pronounced C-type inactivation. These altered gating properties will reduce the delayed-rectifier potassium current which may underlie the symptoms of EA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714564     DOI: 10.1016/s0014-5793(98)00814-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Loss-of-function BK channel mutation causes impaired mitochondria and progressive cerebellar ataxia.

Authors:  Xiaofei Du; Joao L Carvalho-de-Souza; Cenfu Wei; Willy Carrasquel-Ursulaez; Yenisleidy Lorenzo; Naileth Gonzalez; Tomoya Kubota; Julia Staisch; Timothy Hain; Natalie Petrossian; Michael Xu; Ramon Latorre; Francisco Bezanilla; Christopher M Gomez
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-04       Impact factor: 11.205

Review 2.  Mutational consequences of aberrant ion channels in neurological disorders.

Authors:  Dhiraj Kumar; Rashmi K Ambasta; Pravir Kumar
Journal:  J Membr Biol       Date:  2014-08-14       Impact factor: 1.843

3.  Functional analysis of a novel potassium channel (KCNA1) mutation in hereditary myokymia.

Authors:  Haijun Chen; Christian von Hehn; Leonard K Kaczmarek; Laura R Ment; Barbara R Pober; Fuki M Hisama
Journal:  Neurogenetics       Date:  2006-11-29       Impact factor: 2.660

4.  Variable K(+) channel subunit dysfunction in inherited mutations of KCNA1.

Authors:  Ruth Rea; Alexander Spauschus; Louise H Eunson; Michael G Hanna; Dimitri M Kullmann
Journal:  J Physiol       Date:  2002-01-01       Impact factor: 5.182

Review 5.  Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.

Authors:  Niyathi Hegde Shah; Elias Aizenman
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

6.  Episodic ataxia type 1 mutations differentially affect neuronal excitability and transmitter release.

Authors:  Joost H Heeroma; Christian Henneberger; Sanjeev Rajakulendran; Michael G Hanna; Stephanie Schorge; Dimitri M Kullmann
Journal:  Dis Model Mech       Date:  2009-09-24       Impact factor: 5.758

7.  Episodic ataxia type 1 mutations in the human Kv1.1 potassium channel alter hKvbeta 1-induced N-type inactivation.

Authors:  Brooke Maylie; Erinne Bissonnette; Michael Virk; John P Adelman; James G Maylie
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

8.  Nerve excitability studies characterize Kv1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1.

Authors:  Susan E Tomlinson; S Veronica Tan; Dimitri M Kullmann; Robert C Griggs; David Burke; Michael G Hanna; Hugh Bostock
Journal:  Brain       Date:  2010-11-23       Impact factor: 13.501

9.  Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.

Authors:  Tracey D Graves; Yoon-Hee Cha; Angelika F Hahn; Richard Barohn; Mohammed K Salajegheh; Robert C Griggs; Brian N Bundy; Joanna C Jen; Robert W Baloh; Michael G Hanna
Journal:  Brain       Date:  2014-02-26       Impact factor: 13.501

Review 10.  Episodic ataxia type 1: a neuronal potassium channelopathy.

Authors:  Sanjeev Rajakulendran; Stephanie Schorge; Dimitri M Kullmann; Michael G Hanna
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.